Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 649

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 649
---
 (the “January 2024 Representative Warrants”) to purchase 6,260 shares of the Company’s common stock at
an exercise price of $25.41 per share. The January 2024 Representative Warrants are exercisable beginning on January 31, 2024 until January
31, 2029.

The units and pre-funded units were offered
and sold pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-276641), declared effective by the SEC on
January 29, 2024. The closing of the January 2024 Offering occurred on January 31, 2024, generating net proceeds to the Company of
approximately $1.9 million, after deducting underwriting discounts and commissions and the payment of other offering expenses
payable by the Company of approximately $510,000.

On February 1, 2024 and April 9, 2024, the Company
issued 8,326 shares and 8,326 shares of common stock, respectively upon the exercise of 8,326 and 8,326 January 2024 Pre-Funded Warrants,
respectively, resulting in aggregate proceeds to the Company of $9,990.

On April 1, 2024, the Company entered into an
Amendment to the Debt Exchange Agreement with Trevally, LLC (“Trevally”), which amends the original agreement with Trevally
(executed in January 2023). Pursuant to the Amendment, Trevally agreed to return 2,000 shares of the Company’s common stock, initially
issued to Trevally in January 2023 as advance consideration for agreeing to complete the synthesis of research materials for the Company.
Trevally returned the previously issued shares for no consideration on April 3, 2024. Trevally delivered the completed research materials
to the Company on July 1, 2024.

On July 12, 2024, the Company entered into an
At-the-Market Issuance Sales Agreement (the “ATM Agreement”) with WallachBeth Capital LLC as sales agent, to sell shares
of common stock having an aggregate offering price of up to $1,253,603 from time to time, through an “at the market offering”
program (the “ATM Offering”). The offer and sale of shares of common stock from the ATM Offering were made pursuant to the
Company’s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement